Cronus Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 02-01-2025
- Paid Up Capital ₹ 1.50 M
as on 02-01-2025
- Company Age 14 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.67 M
as on 02-01-2025
- Revenue 214.32%
(FY 2022)
- Profit 79.62%
(FY 2022)
- Ebitda 83.75%
(FY 2022)
- Net Worth -2.23%
(FY 2022)
- Total Assets -80.28%
(FY 2022)
About Cronus Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹2.67 M.
Brijal Brahmbhatt, Muneesh Kumar, and Mohit Shah serve as directors at the Company.
- CIN/LLPIN
U24100GJ2010PLC061036
- Company No.
061036
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
08 Jun 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Cronus Biotech Limited offer?
Cronus Biotech Limited offers a wide range of products and services, including Antibiotic Injection, Ceftriaxone Injection, Antibiotic Tablets & Capsules, Azithromycin Tablets, Diclofenac, Diclofenac Sodium Injection, Pharmaceutical Capsules, Softgel Capsules, Vitamin Tablets & Capsules, Vitamin D3 Tablets & Capsules.
Who are the key members and board of directors at Cronus Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Brijal Brahmbhatt  | Director | 15-Oct-2021 | Current |
| Muneesh Kumar | Director | 15-Oct-2021 | Current |
| Mohit Shah | Director | 08-Jun-2010 | Current |
Financial Performance of Cronus Biotech.
Cronus Biotech Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 214.32% increase. The company also saw a substantial improvement in profitability, with a 79.62% increase in profit. The company's net worth dipped by a decrease of 2.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cronus Biotech?
In 2020, Cronus Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Mishkon Research Labs LimitedActive 6 years 3 monthsBrijal Brahmbhatt and Mohit Shah are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 11 Jul 2016 | ₹2.67 M | Open |
How Many Employees Work at Cronus Biotech?
Unlock and access historical data on people associated with Cronus Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cronus Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cronus Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
